Literature DB >> 32315676

Gut Microbiome Composition Is Associated with a Pathologic Response After Preoperative Chemoradiation in Patients with Rectal Cancer.

Bum-Sup Jang1, Ji Hyun Chang2, Eui Kyu Chie3, Kyubo Kim4, Ji Won Park5, Min Jung Kim5, Eun-Ji Song6, Young-Do Nam6, Seung Wan Kang7, Seung-Yong Jeong5, Hak Jae Kim8.   

Abstract

PURPOSE: There are ongoing investigations to find promising biomarkers for predicting a complete response (CR) after concurrent chemoradiation (CCRT) in rectal cancer. We aimed to find the predictive value in the gut microbiome in terms of response after preoperative CCRT. METHODS AND MATERIALS: We collected a total of 45 fecal samples from patients with rectal cancer before CCRT. Tumor response after CCRT was assessed according to the American Joint Committee on Cancer tumor regression grading system. Analysis of linear discriminant analysis effect size and MetaCyc pathway abundance predictions were performed to compare composition and metabolic function of microbiome between patients with and without CR. We also established a Bayesian network model to identify microbial networks and species to be related with CCRT response.
RESULTS: Seven patients (15.6%) demonstrated pathologically CR, and 38 patients (84.4%) showed non-CR after preoperative CCRT. Between CR and non-CR patients, there was a significant difference in terms of β-diversity (P = .028), but no difference in α-diversity was found. Bacteroidales (Bacteroidaceae, Rikenellaceae, Bacteroides) were relatively more abundant in patients with non-CR than those with CR. Pathways related to anabolic function predominated in CR patients. According to Bayesian network analysis, Duodenibacillus massiliensis was linked with the improved CR rate.
CONCLUSIONS: From the fecal microbiome using samples obtained before preoperative CCRT, differences in microbial community composition and functions were observed between patients with and without CR in rectal cancer. However, the finding that a specific taxon may be linked with the improved therapeutic response should be verified in a prospective setting.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32315676     DOI: 10.1016/j.ijrobp.2020.04.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal Cancer.

Authors:  Kasun Wanigasooriya; Joao D Barros-Silva; Louise Tee; Mohammed E El-Asrag; Agata Stodolna; Oliver J Pickles; Joanne Stockton; Claire Bryer; Rachel Hoare; Celina M Whalley; Robert Tyler; Toritseju Sillo; Christopher Yau; Tariq Ismail; Andrew D Beggs
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 2.  Radiotherapy and the gut microbiome: facts and fiction.

Authors:  Jing Liu; Chao Liu; Jinbo Yue
Journal:  Radiat Oncol       Date:  2021-01-13       Impact factor: 3.481

3.  The Gut Microbiome Is Associated With Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients-A Pilot Study.

Authors:  Wei Shi; Lijun Shen; Wei Zou; Jingwen Wang; Jianing Yang; Yuezhu Wang; Bingdong Liu; Liwei Xie; Ji Zhu; Zhen Zhang
Journal:  Front Cell Infect Microbiol       Date:  2020-12-09       Impact factor: 5.293

Review 4.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

5.  Gut Microbiome and Its Associations With Acute and Chronic Gastrointestinal Toxicities in Cancer Patients With Pelvic Radiation Therapy: A Systematic Review.

Authors:  Jinbing Bai; Zahra A Barandouzi; Claire Rowcliffe; Rebecca Meador; Despina Tsementzi; Deborah Watkins Bruner
Journal:  Front Oncol       Date:  2021-12-06       Impact factor: 5.738

Review 6.  Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia coli in Colorectal Cancer.

Authors:  Julie Veziant; Romain Villéger; Nicolas Barnich; Mathilde Bonnet
Journal:  Cancers (Basel)       Date:  2021-05-05       Impact factor: 6.639

Review 7.  The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review.

Authors:  Byeongsang Oh; Thomas Eade; Gillian Lamoury; Susan Carroll; Marita Morgia; Andrew Kneebone; George Hruby; Mark Stevens; Frances Boyle; Stephen Clarke; Brian Corless; Mark Molloy; David Rosenthal; Michael Back
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

Review 8.  Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.

Authors:  Romain Daillère; Bertrand Routy; Anne-Gaëlle Goubet; Alexandria Cogdill; Gladys Ferrere; Carolina Alves-Costa Silva; Aurélie Fluckiger; Pierre Ly; Yacine Haddad; Eugenie Pizzato; Cassandra Thelemaque; Marine Fidelle; Marine Mazzenga; Maria Paula Roberti; Cléa Melenotte; Peng Liu; Safae Terrisse; Oliver Kepp; Guido Kroemer; Laurence Zitvogel; Lisa Derosa
Journal:  Oncoimmunology       Date:  2020-07-20       Impact factor: 8.110

Review 9.  Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients.

Authors:  Aylin Alkan; Tobias Hofving; Eva Angenete; Ulf Yrlid
Journal:  Biomark Res       Date:  2021-07-28

Review 10.  Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease.

Authors:  Antonio Enrico Zaurito; Markus Tschurtschenthaler
Journal:  Metabolites       Date:  2022-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.